Clinical trials: Cardiac Ischemia
Coronary Atherosclerosis
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries.
- Trial name
- NEVO RES-I (NCT00606333)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System, Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
- Where
- 2 sites in Brazil, New Zealand
- Volunteers
- 394 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI)
The Efficacy and Safety Evaluation of 5G Tele-PCI Using R-OneTM
Patients with coronary artery disease requiring PCI treatment were enrolled in the study. All patients underwent PCI with the robotic R-OneTM System (R-One Vascular Robotics, Cathbot).
- Trial name
- tele-PCI (NCT07132255)
- Testing
- R-One assisted tele-PCI, R-One assisted on-site PCI
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Cathbot (Shanghai) Robot Co., Ltd
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Left Ventricular Dysfunction
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic lesion.
- Trial name
- NCT00938847
- Testing
- PCI
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Asklepios proresearch
Coronary Artery Disease
NAVIGATE GRX Study
The objective of the present study is to detail the results of robotic-assisted PCI using technIQ automated movements in real-world clinical practice.
- Trial name
- NCT04883008
- Testing
- CorPath GRX with technIQ automated movements enabled (technIQ ON), CorPath GRX with technIQ automated movements disabled (technIQ OFF).
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
STEMI - ST Elevation Myocardial Infarction
Semi Occlusion of the Coronary Sinus as an Adjunct to PCI in STEMI Patients, FIH Clinical Study
The present study is planned to evaluate the safety and feasibility of the Booster Balloon catheter when applied to STEMI patients.
- Trial name
- NCT05557019
- Testing
- Booster Balloon Catheter
- Where
- 2 sites in Georgia, Israel
- Volunteers
- 20 people
- Sponsor
- Intratech Medical Ltd.
Acute Coronary Syndrome
99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I Test
Prospective multicenter sample collection and testing study.
- Trial name
- NCT02638311
- Where
- 3 sites in United States
- Volunteers
- 769 people, healthy volunteers welcome
- Sponsor
- Trinity Biotech
Coronary Stenosis, Drug-coated Balloon
Bingo Drug-Coated Balloon in Real World
The purpose is to observe and evaluate the safety and efficacy of Bingo drug-coated balloon in the real world.
- Conditions
- Coronary Stenosis, Drug-coated Balloon, De Novo Stenosis, Coronary Artery Disease in Transplanted Heart Accelerated
- Trial name
- NCT04234893
- Where
- China
- Volunteers
- 805 people
- Sponsor
- Yinyi(Liaoning) Biotech Co., Ltd.
Coronary Artery Disease, Occlusion of Artery
Saphenous Vein Allografts for Coronary Bypass
The primary objective of this observational study is to evaluate the function (patency) of cryopreserved saphenous vein allografts used as coronary artery bypass grafts (CABG) for patients with occlusive coronary artery disease.
- Trial name
- NCT01386021
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- CryoLife, Inc.
Coronary Artery Disease, Diagnosis
Evaluating AI-Gatekeeper Software in Coronary Artery Stenosis Screening: A Multicenter RCT
The purpose of this study is to determine the efficacy, safety, and cost-effectiveness of AI-Gatekeeper software to assist clinicians in the diagnosis of coronary artery disease by predicting coronary artery stenosis (≥50%) from…
- Trial name
- AIGatekeeper (NCT06178900)
- Testing
- Assisted by the AI-Gatekeeper software group
- Where
- 5 sites in South Korea
- Volunteers
- 450 people
- Sponsor
- INFINITT Healthcare
Acute Coronary Syndrome
Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome
This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia.
- Trial name
- Zeus-ACS (NCT00514501)
- Testing
- Iodofiltic acid I 123
- Where
- 38 sites in United States, Canada
- Volunteers
- 510 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Myocardial Infarction
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
The study is testing the effect of ziltivekimab on reducing plaque in the blood vessels of the heart, specifically aiming to manage or reduce atherosclerotic plaque.
- Trial name
- ZEPHYR (NCT07301034)
- Testing
- Ziltivekimab
- Where
- 20 sites in Austria, Denmark and 4 more
- Volunteers
- 332 people
- Sponsor
- Novo Nordisk A/S
Cardiovascular Risk Factor, Cardiovascular Diseases
Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with CVD, or at high risk for CVD, on a…
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
- Trial name
- LIBerate-HR (NCT04806893)
- Testing
- lerodalcibep
- Where
- 6 sites in United States, India and 1 more
- Volunteers
- 900 people
- Sponsor
- LIB Therapeutics LLC
Heart Disease, Ischemic, Ischemia, Myocardial
The Ischemia Modified Albumin In Diagnosing Ischemic New Events
The purpose of the study is to evaluate the utility of Ischemia Modified Albumin (IMA) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and…
- Conditions
- Heart Disease, Ischemic, Ischemia, Myocardial, Ischemic Heart Disease, Unstable Angina
- Trial name
- IMAgine (NCT00355992)
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,250 people
- Sponsor
- Inverness Medical Innovations
Dyslipidemias
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
A study of the long-term (1 year) effectiveness of atorvastatin to keep patients of high cardiovascular risk at the LDL cholesterol goal of <115 mg/dL
- Trial name
- NCT00644709
- Testing
- Atorvastatin
- Where
- 15 sites in Belgium
- Volunteers
- 196 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Artery Disease
The Optical Coherence Tomography Drug Eluting Stent Investigation
The objective of this study is to evaluate the completeness of struts coverage and vessel wall response to the new generation JACTAX drug-eluting stent vs Taxus stent in de novo coronary artery lesions at 6 months post index…
- Trial name
- OCTDESI (NCT00776204)
- Testing
- JACTAX Drug eluting stent, JACTAX LD drug eluting stent, Taxus Libertè
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Boston Scientific Corporation
Cardiovascular Diseases, Coronary Artery Disease
EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits With DuraGraft [VASC]
The DuraGraft® Registry is a European registry of patients who have undergone CABG and whose vascular grafts have been treated with DuraGraft. All participating sites will be from countries in Europe.
- Trial name
- VASC (NCT02922088)
- Testing
- DuraGraft
- Where
- 36 sites in Austria, Germany and 6 more
- Volunteers
- 2,964 people
- Sponsor
- Somahlution LLC
Angina Pectoris, Coronary Artery Disease
A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)
This study will evaluate the efficacy of ranolazine compared to placebo on duration of exercise assessed by exercise tolerance testing (ETT) at anticipated peak ranolazine plasma concentration after 12 weeks of treatment in…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT01334203
- Testing
- Ranolazine
- Sponsor
- Gilead Sciences
Acute Myocardial Infarction, STEMI
A Study of Acute Myocardial Infarction Using FDY-5301
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.
- Trial name
- NCT03470441
- Testing
- FDY-5301
- Where
- 23 sites in United States, Hungary and 2 more
- Volunteers
- 120 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Cardiovascular Disease, de Novo Coronary Lesions
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical…
- Trial name
- ARRIVE 2 (NCT00569751)
- Testing
- TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System
- Where
- 53 sites in United States
- Volunteers
- 5,016 people
- Sponsor
- Boston Scientific Corporation